ATAI vs LLY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
ATAI's Advanced Deterministic Scorecard reveals severe financial distress: a Piotroski F-Score of 1/9 indicates extreme operational weakness, and the absence of an Altman Z-Score (with negative profitability and massive losses) raises significant bankruptcy risk. Despite a strong analyst consensus of 'strong_buy' and a high target price of $13.45, the company exhibits no profitability, negative margins, and a 620.8% YoY EPS decline, with earnings surprises consistently negative. The stock trades at an inflated Price/Sales of 327.77 and a Price/Book of 6.04, suggesting extreme overvaluation relative to fundamentals. Insider selling in the last six months further undermines confidence in management's view of the company's prospects.
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
ATAI vs LLY: Head-to-Head Comparison
This page compares AtaiBeckley Inc. (ATAI) and Eli Lilly and Company (LLY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.